NWAM LLC’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.56M | Buy |
20,962
+183
| +0.9% | +$40.6K | 0.26% | 97 |
|
|
2025
Q4 | $4.65M | Sell |
20,779
-80
| -0.4% | -$18.2K | 0.26% | 90 |
|
|
2025
Q3 | $4.84M | Sell |
20,859
-641
| -3% | -$131K | 0.26% | 96 |
|
|
2025
Q2 | $4.04M | Buy |
21,500
+1,122
| +6% | +$209K | 0.23% | 108 |
|
|
2025
Q1 | $4.27M | Sell |
20,378
-368
| -2% | -$71.5K | 0.37% | 60 |
|
|
2024
Q4 | $3.69M | Buy |
20,746
+466
| +2% | +$85.7K | 0.23% | 99 |
|
|
2024
Q3 | $4M | Buy |
20,280
+4,865
| +32% | +$908K | 0.24% | 91 |
|
|
2024
Q2 | $2.64M | Buy |
15,415
+5,397
| +54% | +$894K | 0.78% | 27 |
|
|
2024
Q1 | $1.66M | Sell |
10,018
-4,919
| -33% | -$848K | 0.13% | 152 |
|
|
2023
Q4 | $2.31M | Sell |
14,937
-209
| -1% | -$30.5K | 0.19% | 112 |
|
|
2023
Q3 | $2.26M | Buy |
15,146
+69
| +0.5% | +$10.1K | 0.23% | 98 |
|
|
2023
Q2 | $2.03M | Buy |
15,077
+6,337
| +73% | +$929K | 0.17% | 131 |
|
|
2023
Q1 | $1.39M | Sell |
8,740
-6,410
| -42% | -$980K | 0.14% | 150 |
|
|
2022
Q4 | $2.45M | Sell |
15,150
-747
| -5% | -$115K | 0.22% | 114 |
|
|
2022
Q3 | $2.13M | Buy |
15,897
+718
| +5% | +$103K | 0.2% | 110 |
|
|
2022
Q2 | $2.33M | Sell |
15,179
-1,713
| -10% | -$262K | 0.22% | 99 |
|
|
2022
Q1 | $2.74M | Buy |
16,892
+1,042
| +7% | +$151K | 0.21% | 108 |
|
|
2021
Q4 | $2.15M | Buy |
15,850
+2,647
| +20% | +$313K | 0.17% | 140 |
|
|
2021
Q3 | $1.42M | Buy |
13,203
+161
| +1% | +$18.4K | 0.13% | 169 |
|
|
2021
Q2 | $1.47M | Sell |
13,042
-1,068
| -8% | -$120K | 0.14% | 162 |
|
|
2021
Q1 | $1.53M | Buy |
14,110
+1,680
| +14% | +$180K | 0.15% | 151 |
|
|
2020
Q4 | $1.33M | Sell |
12,430
-1,261
| -9% | -$121K | 0.15% | 149 |
|
|
2020
Q3 | $1.2M | Sell |
13,691
-28,005
| -67% | -$2.64M | 0.2% | 121 |
|
|
2020
Q2 | $4.09M | Buy |
41,696
+21,100
| +102% | +$1.86M | 0.57% | 38 |
|
|
2020
Q1 | $1.57K | Sell |
20,596
-1,411
| -6% | -$120K | 0.04% | 108 |
|
|
2019
Q4 | $1.95M | Sell |
22,007
-3,117
| -12% | -$259K | 0.34% | 65 |
|
|
2019
Q3 | $1.9M | Buy |
25,124
+14,884
| +145% | +$1.02M | 0.36% | 63 |
|
|
2019
Q2 | $745K | Buy |
10,240
+439
| +4% | +$34.5K | 0.15% | 147 |
|
|
2019
Q1 | $790K | Buy |
9,801
+127
| +1% | +$10.4K | 0.17% | 132 |
|
|
2018
Q4 | $892K | Buy |
9,674
+420
| +5% | +$36.9K | 0.23% | 103 |
|
|
2018
Q3 | $875K | Buy |
9,254
+947
| +11% | +$89.8K | 0.2% | 112 |
|
|
2018
Q2 | $770K | Buy |
8,307
+4,908
| +144% | +$479K | 0.18% | 128 |
|
|
2018
Q1 | $322K | Sell |
3,399
-2,088
| -38% | -$229K | 0.08% | 236 |
|
|
2017
Q4 | $531K | Buy |
5,487
+176
| +3% | +$16.6K | 0.13% | 163 |
|
|
2017
Q3 | $472K | Buy |
5,311
+776
| +17% | +$59.1K | 0.12% | 168 |
|
|
2017
Q2 | $329K | Buy |
+4,535
| New | +$305K | 0.06% | 207 |
|
|
2014
Q4 | – | Sell |
-8,501
| Closed | -$491K | – | 242 |
|
|
2014
Q3 | $491K | Sell |
8,501
-261
| -3% | -$14.5K | 0.17% | 137 |
|
|
2014
Q2 | $495K | Sell |
8,762
-410
| -4% | -$21.5K | 0.15% | 145 |
|
|
2014
Q1 | $471K | Buy |
+9,172
| New | +$464K | 0.16% | 136 |
|
|
2013
Q4 | – | Sell |
-5,403
| Closed | -$242K | – | 180 |
|
|
2013
Q3 | $242K | Sell |
5,403
-443
| -8% | -$19.6K | 0.12% | 148 |
|
|
2013
Q2 | $242K | Buy |
+5,846
| New | +$256K | 0.12% | 147 |
|
Other funds holding ABBV
VCM
VPM
NWAM LLC's ABBV Position: Q1 2026 in Review
NWAM LLC increased its AbbVie (ABBV) stake by 0.88% in Q1 2026, buying an estimated $40.6K and bringing the position to 20,962 shares worth $4.56M. The position accounts for 0.26% of the portfolio, ranked #97.
NWAM LLC first reported a position in ABBV in Q2 2013 and has held it in 41 quarters since. The position peaked at $4.84M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- NWAM LLC held 20,962 shares of AbbVie worth $4.56M as of Q1 2026.
- NWAM LLC bought 183 AbbVie shares in Q1 2026, an estimated $40.6K.
- AbbVie made up 0.26% of NWAM LLC's portfolio in Q1 2026, its #97 holding.
- NWAM LLC first reported a position in AbbVie in Q2 2013 and has held it in 41 quarters since.
- NWAM LLC's AbbVie position peaked at $4.84M in Q3 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on NWAM LLC's 13F filing for Q1 2026, filed 4 May 2026.